Assessment of the Diagnostic Value of Plasma Levels, Activities, and Their Ratios of von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction

Background and Objectives: Raised levels of von Willebrand factor (VWF) and reduced levels of a disintegrin and a metalloproteinase with a thrombospondin type I motif, member 13 (ADAMTS13) activity are associated with thrombosis. We aimed to investigate the relationships between plasma levels of VWF and ADAMTS13, their ratios, and the occurrence of cerebral infarction and to understand the roles of VWF and ADAMTS13 in cerebral infarction. Methods: Ninety-four patients with cerebral infarction and 103 controls were analyzed. Plasma levels of VWF antigen (VWF: Ag), VWF ristocetin cofactor activity (VWF: Rcof), and VWF collagen binding activity (VWF: CB) were measured by enzyme-linked immunosorbent assay (ELISA). The ADAMTS13 activity (ADAMTS13) was measured with FRETS-VWF73. The relationship between plasma levels and ratios of VWF and ADAMTS13 and the occurrence of cerebral infarction were analyzed. Results: Patients with cerebral infarction displayed higher VWF: Ag and VWF: Rcof levels and lower ADAMTS13, VWF: CB/VWF: Ag, ADAMTS13/VWF: Ag, and ADAMTS13/VWF: Rcof levels compared to controls (P < .01). The highest quartiles of VWF: Ag (odds ratio [OR] = 5.11, 95% confidence interval [CI], 1.49-17.50) and VWF: Rcof (OR = 5.04, 95% CI, 1.62-15.66) and the lowest quartiles of VWF: CB/VWF: Ag (OR = 5.91, 95% CI, 1.95-17.93), ADAMTS13/VWF: Ag (OR = 9.11, 95% CI, 2.49-33.33), and ADAMTS13/VWF: Rcof (OR = 3.73, 95% CI, 1.39-10.03) are associated with cerebral infarction. Conclusions: An association was found between reduced levels of VWF: CB/VWF: Ag, ADAMTS13/VWF: Ag, and ADAMTS13/VWF: Rcof ratios and cerebral infarction. Our data suggest that increased levels of VWF and reduced levels of ADAMTS13 activity may contribute to the pathogenesis of cerebral infarction.

[1]  F. Leebeek,et al.  Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. , 2014, Blood reviews.

[2]  C. Leissinger,et al.  Factor VIII in the Setting of Acute Ischemic Stroke Among Patients With Suspected Hypercoagulable State , 2014, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[3]  Lasek-Bal Anetta,et al.  Elevated factor VIII level and stroke in patients without traditional risk factors associated with cardiovascular diseases , 2013, Neuropsychiatric Disease and Treatment.

[4]  D. Motto,et al.  ADAMTS13 reduces VWF‐mediated acute inflammation following focal cerebral ischemia in mice , 2012, Journal of thrombosis and haemostasis : JTH.

[5]  Shun-dong Ji,et al.  Development of an ELISA method for testing VWF ristocetin cofactor activity with improved sensitivity and reliability in the diagnosis of von Willebrand disease , 2012, European journal of haematology.

[6]  Elsayed Z Soliman,et al.  Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study. , 2012, International journal of cardiology.

[7]  S. D. De Meyer,et al.  von Willebrand Factor: An Emerging Target in Stroke Therapy , 2012, Stroke.

[8]  J. Tanguay,et al.  An Anti-von Willebrand Factor Aptamer Reduces Platelet Adhesion Among Patients Receiving Aspirin and Clopidogrel in an Ex Vivo Shear-Induced Arterial Thrombosis , 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[9]  B. Nieswandt,et al.  Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke , 2011, Journal of thrombosis and haemostasis : JTH.

[10]  F. Peyvandi,et al.  Role of von Willebrand factor in the haemostasis. , 2011, Blood transfusion = Trasfusione del sangue.

[11]  C. Blomstrand,et al.  Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke , 2011, Journal of thrombosis and haemostasis : JTH.

[12]  J. Deckers,et al.  Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. , 2009, Atherosclerosis.

[13]  K. Zou,et al.  Receiver-Operating Characteristic Analysis for Evaluating Diagnostic Tests and Predictive Models , 2007, Circulation.

[14]  K. Kaikita,et al.  Reduced von Willebrand factor‐cleaving protease (ADAMTS13) activity in acute myocardial infarction , 2006, Journal of thrombosis and haemostasis : JTH.

[15]  Alan D. Lopez,et al.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data , 2006, The Lancet.

[16]  Giuseppe Lippi,et al.  Von Willebrand factor and thrombosis , 2006, Annals of Hematology.

[17]  Yoshihiro Kokubo,et al.  FRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assay , 2005, British journal of haematology.

[18]  Z. Ruggeri,et al.  Von Willebrand factor, platelets and endothelial cell interactions , 2003, Journal of thrombosis and haemostasis : JTH.

[19]  H. Schwarz,et al.  Comparative Study on Collagen-Binding Enzyme-Linked Immunosorbent Assay and Ristocetin Cofactor Activity Assays for Detection of Functional Activity of von Willebrand Factor , 2002, Seminars in thrombosis and hemostasis.

[20]  S. Duffy,et al.  Von Willebrand factor and risk of ischemic stroke , 1997, Neurology.

[21]  J. Scott,et al.  Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets. , 1991, The Journal of biological chemistry.

[22]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.